Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine with or without fosaprepitant for CINV prevention
NCT03578081Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Cancer and Leukemia Group B. Started Nov 2018; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03578081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578081.